## PHARMACY CHAIN $36 \cdot 6$

## CORPORATE PROFILE

HEALTHY, FIT \& STRONG

SEPTEMBER 2007

## THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION, AND IS NOT AN OFFER TO SELL, OR AN INVITATION TO MAKE OFFERS TO PURCHASE, ANY SECURITIES IN THE RUSSIAN FEDERATION. <br> NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

This document includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the fact that they do not only relate to historical or current events. Forward-looking statements often use words such as" anticipate", "target", "expect", "estimate", "intend", "expected", "plan", "goal" believe", or other words of similar meaning. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances, a number of which are beyond Company's control. As a result, actual future results may differ materially from the plans, goals and expectations set out in these forward-looking statements. Any forward-looking statements made by or on behalf of the Company speak only as at the date of this announcement. Save as required by any applicable laws or regulations, the Company undertakes no obligation publicly to release the results of any revisions to any forward-looking statements in this document that may occur due to any change in its expectations or to reflect events or circumstances after the date of this document.

The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States.

This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments, i.e., investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (c) high net worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as "relevant persons"). The securities are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.

## 3

### 36.6 AT A GLANCE



## GROWTH DRIVERS

GDP per Capita
2006 \$7,200
Disposable Income
CAGR 14-16\%
Pharma market
2007E \$14.0bln
Pharma market
CAGR 12-15\%
$\square$ Growing disposable income pushes consumption up

B Booming H\&B and Pharma industry followed by changes in consumer's behaviour
$\square$ Improving economy in the regions provide for better opportunities of consolidation

- Scale effect together with internal improvements in operations management ensure higher future profitability


## 5

## STORES GROWTH

FY06 Sales breakdown


## REGIONAL EXPANSION

## Business-Units

| MOSCOW 374 |  |
| ---: | ---: |
| URALS 336 |  |
| VOLGA 131 |  |
| SOUTH 132 |  |
| WEST. SIBERIA 42 |  |
| NORTH-WEST 32 |  |
|  |  |
| the Company reaches |  |
| out to every Russian |  |
| city with a population |  |
| of over 500K people to |  |
| enjoy 10-20\% of the |  |
| region's pharmacy |  |
| retail market |  |



## SALES BREAK-DOWN

## RETAIL



## GROSS MARGIN

## RETAIL



## 9

## COMPETITION

Regional
penetration will be
achieved both
through organic
openings and
acquisitions of the
regional chains
This is subject to
successful
competition with a
few other chains
developing
nationwide

Pharmexpert, company estimations

Sales PRO-FORMA USD min

500


300

200

100


400


## BRAND \& CUSTOMERS




Shopping experience


11

## DIFFERENTIATION

New projects launched by 36.6 aimed to differentiate our product assortment and to obtain higher gross margins

Boots brands 600 SKU's of Boots products are sold countrywide


## Exclusive offerings

Eclipse, Monteil, Champneys implants etc


CHAMPNEYS

- collection -

Optics
7 stores and 22 opticians departments


12

## DIFFERENTIATION

## PRIVATE LABEL

We target the most successful product categories to launch private label products

- 210 SKU`s available
- 2.5 mln - sales volume in 2006
- 67\% - average gross margin
- over 150 products in pipeline
- 10\% - share in retail sales by 2011


## Basic H\&B



Natura \& MedResponse


## Parapharma \& OTC



Convenience goods


## DIVERSIFICATION

MEDICAL SERVICES


In July 2006 we acquired one of the best Moscow private clinics providing medical, surgical and dental services through EMC \& EDC as well as full-scale laboratory

FY'06
SALES
EBITDA
\$21mln
22\%

## Market

- fragmented with no potential core for consolidation
- non-satiated rapidly growing demand
- disturbed national healthcare system


## Rationale/Strategy

- realize synergies between retail and medical services businesses by launching a chained operator in "masstige" market segment


## 14

## DIVERSIFICATION

NEW PROJECTS

- Number of stores to be opened
- 01.01.06
- franchise experience

ELC Stores

- 01.07.07
- 01.01 .08 (plan) 8
- 01.01.09 (plan)
- adjacent to pharmacy retail market segment
- exclusive child's play assortment for pharmacies
- own logistics and import operations
in USD mln.


NET SALES 11.7
GROSS MARGIN
PROFIT $12 \%$

- Investments in 1 store \$160 K
- Return of investments 3-4 years


## 15

## DIVERSIFICATION NEW PROJECTS

- new format: discounter pharmacy and wide range of FMCG
- low level of opening expenses
- efficient operations in the larger stores in the regions
- 54\% - sales increase $y-0-y$
- 17\% - gross margin


## MILA Stores

3 stores in Povoljie



## 16

## LOGISTICS

In 2006 we started own supply chain system development

- invested $\$ 10 \mathrm{mln}$; additional $\$ 10 \mathrm{mln}$ will be invested in 1-1,5 years
- higher margins secured
- exclusive assortment deliveries
- payback in 3 years



## DISTRIBUTION SYSTEM <br> turnover arrangement



Supplier
Purchase agreement with ZAO «Apteki«36,6»

Regional wholesalers of holding.
The purchase agreement with ZAO «Apteki«36,6»

Regional crossdocking centers


RC "Shenker" the transport expedition contract with ZAO «Apteki«36,6»



The purchase agreement between the wholesaler and pharmacy chain in region


## 18

## BOARD OF DIRECTORS

Decision making is ensured by the balanced opinion of both shareholders and that of independent directors

## Sergey KRIVOSHEEV

Chairman, Co-founder


Michael OBERMAYER Independent director, Director Emeritus of McKinsey \& Company

## Vassily RUDOMINO, Independent director, Partner in ALRUD law firm

Vladimir STOLIN, Independent director, Chairman in ECOPSY consulting firm

## MANAGEMENT STRUCTURE

Planning and operational controls are performed across the regional business units and product categories

Brand integrity and management as well as strategic business development and expansion are corporate major priorities

## ARTEM BEKTEMIROV

 CEOANTON PARKANSKY
Managing director

DMITRY GODUNOV
Operations

ALEXANDRA
KOZHAEVA
Commercial director Cor

SBORETS YULIA
CFO

NATALIA MAKAROVA
Human Resources

BORIS RYABOV
Business Technology
Development

KIRILL LEVASHOV
Medical director

VICTOR VASILIEV
Legal Council

## OLEG ANIKIN

Strategy

MAXIM ARKHIPOV
Corporate Finance
\& Investor Relations

## ELENA KUKOL

Marketing


20

## PHARMACY CHAIN $36 \cdot 6$

## FINANCIALS \& ANALYSIS



Please note:
reporting under IFRS since 2002
auditor Deloitte

1H2007 financials are non-audited
data by segments requires certain adjustments

## 21

## INCOME STATEMENT

 CONSOLIDATED\section*{| 1H07 | 1H06 | $07 / 06$ | 2006 | 2005 | 2004 | 2003 | 2002 |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |}


| REVENUE | 390.5 | 218.6 | $79 \%$ | 528.9 | 305.2 | 211.0 | 147.8 | 118.7 |
| ---: | ---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| GROSS PROFIT | 130.9 | 78.8 | $66 \%$ | 183.4 | 117.8 | 80.2 | 59.8 | 46.0 |
| EBITDA | 15.0 | 9.2 | $64 \%$ | 25.5 | 23.3 | 18.5 | 13.6 | 15.1 |
|  | $3.8 \%$ | $4.2 \%$ |  | $4.8 \%$ | $7.6 \%$ | $8.8 \%$ | $9.2 \%$ | $12.7 \%$ |
| OPERATING INCOME | 6.5 | 4.2 | $56 \%$ | 12.5 | 13.8 | 11.5 | 8.4 | 10.4 |
| SALE OF INV. | - | 53.1 |  | 53.1 | 15.8 | - | - | - |
| NET INCOME | -16.9 | 49.5 | $n / a$ | 34.5 | 8.3 | 0.7 | 1.0 | 3.3 |
|  | $-4.3 \%$ | $22.6 \%$ |  | $6.5 \%$ | $2.7 \%$ | $0.3 \%$ | $0.7 \%$ | $2.8 \%$ |

in USD min.

## INCOME STATEMENT

CONSOLIDATED \& SEGMENTED

## 1H07 Retail VERO EMC N-Core Corp

| REVENUE | 390.5 | 302.9 | 59.5 | 12.7 | 15.4 |  |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| GROSS PROFIT | 130.9 | 83.4 | 36.6 | 6.9 | 4.0 |  |
|  | $33.5 \%$ | $27.5 \%$ | $61.5 \%$ | $54.7 \%$ | $26.0 \%$ |  |
| EBITDA | 15.0 | -3.0 | 17.0 | 3.5 | -0.4 | -2.1 |
|  | $3.8 \%$ | $-1.0 \%$ | $28.6 \%$ | $27.6 \%$ | $-2.6 \%$ | $n / a$ |
| OPERATING INCOME | 6.5 | -9.3 | 15.2 | 3.2 | -0.4 | -2.2 |
| NET INCOME | -16.9 | -12.5 | 11.0 | 2.3 | -0.6 | -17.1 |
|  |  |  |  |  |  |  |
| in USD min. |  |  |  |  |  |  |

23

## BALANCE SHEET <br> consolidated

|  | H107 | 2006 | 2005 | 2004 | 2003 | 2002 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| N-CURRENT ASSETS | 325.2 | 286.6 | 125.3 | 99.8 | 60.1 | 45.9 |
| CURRENT ASSETS | 295.3 | 238.7 | 119.4 | 72.5 | 53.0 | 38.8 |
| TOTAL ASSETS | 620.4 | 525.3 | 244.7 | 172.3 | 113.1 | 84.7 |
| EQUITY | 71.5 | 88.4 | 48.4 | 43.5 | 40.2 | 24.7 |
| TOTAL DEBT | 287.3 | 253.1 | 109.9 | 80.4 | 43.1 | 36.0 |
| C-NT LIABILITIES* | 142.9 | 131.8 | 64.5 | 40.0 | 24.9 | 20.1 |
| in USD min. | * Current Liabilities are non-interest bearing liabilities |  |  |  |  |  |

## 24 <br> BALANCE SHEET <br> consolidated



## 25

## CASH FLOW <br> CONSOLIDATED \& SEGMENTED

## 2006 Retail $\quad$ VERO $\quad$ EMC $\quad$ N-Core $\quad$ Corp

| profit before tax | 51.6 | -21.5 | 23.3 | 2.4 | -1.3 | 48.7 |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| profit before wCC | 27.6 | -1.3 | 30.8 | 2.7 |  | -4.6 |
| NET CASH in OA | -43.8 | -32.4 | -0.7 | 8.0 | -5.7 | -13.0 |
| NET CASH in IA | -84.8 | -137.9 | -4.8 | -0.2 | -0.4 | 58.5 |
| NET CASH from FA | 128.3 | 13.1 | 3.4 | -2.4 |  | 114.1 |
| net cash | 5.1 | 7.4 | -0.1 | 0.5 | 0.8 | -3.4 |

## 26 <br> INCOME STATEMENT <br> RETAIL

\section*{| 1H07 | 1H06 | $07 / 06$ | 2006 | 2005 | 2004 | 2003 | 2002 |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |}


| REVENUE | 302.9 | 157.8 | $92 \%$ | 386.2 | 203.2 | 134.3 | 81.9 | 58.8 |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| GROSS PROFIT | 83.4 | 48.4 | $72 \%$ | 112.2 | 67.2 | 45.4 | 26.3 | 19.2 |
|  | $27.5 \%$ | $30.7 \%$ |  | $29.1 \%$ | $33.1 \%$ | $33.8 \%$ | $32.1 \%$ | $33 \%$ |
| EBITDA | -3.0 | -0.1 | $n / a$ | -1.2 | 2.9 | 6.4 | 1.8 | 2.6 |
|  | $-1.0 \%$ | $-0.1 \%$ |  | $-0.3 \%$ | $1.4 \%$ | $4.8 \%$ | $2.2 \%$ | $4.4 \%$ |
| OPERATING INCOME | -9.3 | -4.6 | $n / a$ | -10.2 | -2.5 | 2.6 | -0.2 | 0.9 |

in USD mln.

KEY PERFORMANCE INDICATORS


## 28

## BALANCE SHEET

## RETAIL

| $1 H 07$ | 2006 | 2005 | 2004 | 2003 | 2002 |
| :--- | :--- | :--- | :--- | :--- | :--- |


| N-CURRENT ASSETS | 258.3 | 226.3 | 85.4 | 59.5 | 21.9 | 15.7 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| CURRENT ASSETS | 175.9 | 136.0 | 52.4 | 29.1 | 15.6 | 13.1 |
| TOTAL ASSETS | 434.2 | 362.3 | 137.8 | 88.6 | 37.4 | 28.8 |
| LONG-TERM LIAB. | 5.2 | 4.8 | 4.6 | 4.7 | 1.9 | 11.1 |
| C-NT LIABILITIES | 166.5 | 136.1 | 58.2 | 27.3 | 35.3 | 15.2 |

## 29

## INCOME STATEMENT

VEROPHARM

\section*{| 1H07 | 1H06 | $07 / 06$ | 2006 | 2005 | 2004 | 2003 | 2002 |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |}


| REVENUE | 59.5 | 45.2 | $32 \%$ | 100.5 | 79.4 | 59.9 | 52.8 | 43.9 |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| GROSS PROFIT | 36.6 | 27.8 | $32 \%$ | 60.1 | 47.0 | 32.7 | 31.3 | 23.4 |
|  | $61.5 \%$ | $61.4 \%$ |  | $59.8 \%$ | $59.2 \%$ | $54.5 \%$ | $59.2 \%$ | $53.3 \%$ |
| EBITDA | 17.0 | 12.3 | $39 \%$ | 29.2 | 25.1 | 17.8 | 15.7 | 13.5 |
|  | $28.6 \%$ | $27.1 \%$ |  | $29.1 \%$ | $31.6 \%$ | $29.7 \%$ | $29.7 \%$ | $30.9 \%$ |
| OPERATING INCOME | 15.2 | 11.1 | $37 \%$ | 25.7 | 21.3 | 14.8 | 12.7 | 10.5 |

in USD mln.

## BALANCE SHEET <br> VEROPHARM

| $1 H 07$ | 2006 | 2005 | 2004 | 2003 | 2002 |
| :--- | :--- | :--- | :--- | :--- | :--- |


| N-CURRENT ASSETS | 41.7 | 40.3 | 35.6 | 35.9 | 34.4 | 31.2 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| CURRENT ASSETS | 91.4 | 82.2 | 54.6 | 38.7 | 32.4 | 23.4 |
| TOTAL ASSETS | 133.1 | 122.5 | 90.2 | 74.6 | 66.8 | 54.5 |
| C-NT LIABILITIES | 22.5 | 22.0 | 16.3 | 20.4 | 20.1 | 6.5 |

31

## INCOME STATEMENT

 NON-CORE \& MEDICAL SERVICES| 1H07 | 1H06 | $07 / 06$ | 2006 | 2005 | EMC 1H07 |
| :--- | :--- | :--- | :--- | :--- | :--- |


| REVENUE | 15.4 | 15.6 | $-1 \%$ | 33.1 | 24.2 |  |
| ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| GROSS PROFIT | 4.0 | 2.6 | $54 \%$ | 5.5 | 3.7 |  |
|  | $26.0 \%$ | $16.8 \%$ |  | $16.5 \%$ | $15.1 \%$ |  |
| EBITDA | -0.4 | -0.2 | $n / a$ | -0.6 | -0.1 |  |
|  | $-2.6 \%$ | $-1.2 \%$ |  | $-1.9 \%$ | $-0.5 \%$ |  |
| OPERATING INCOME | -0.4 | -0.7 | $n / a$ | -0.7 | -0.2 |  |

Address: 119530, Moscow, Ochakovskoye shosse, 10-2-1

Tel.: +7 (495) 792-5207
Fax: +7 (495) 792-5206
E-mail: ir@oao366.ru
www.pharmacychain366.ru
www.oao366.ru

